SG11202007178VA - Compositions and methods of enhancing 5-hydroxytryptophan bioavailability - Google Patents
Compositions and methods of enhancing 5-hydroxytryptophan bioavailabilityInfo
- Publication number
- SG11202007178VA SG11202007178VA SG11202007178VA SG11202007178VA SG11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA SG 11202007178V A SG11202007178V A SG 11202007178VA
- Authority
- SG
- Singapore
- Prior art keywords
- hydroxytryptophan
- bioavailability
- enhancing
- compositions
- methods
- Prior art date
Links
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 title 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623073P | 2018-01-29 | 2018-01-29 | |
| US201862743816P | 2018-10-10 | 2018-10-10 | |
| PCT/US2019/015391 WO2019148087A1 (fr) | 2018-01-29 | 2019-01-28 | Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007178VA true SG11202007178VA (en) | 2020-08-28 |
Family
ID=67395723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007178VA SG11202007178VA (en) | 2018-01-29 | 2019-01-28 | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11337963B2 (fr) |
| EP (1) | EP3746058B1 (fr) |
| JP (2) | JP2021511365A (fr) |
| KR (1) | KR20200116110A (fr) |
| CN (1) | CN111902137A (fr) |
| AU (1) | AU2019211458A1 (fr) |
| BR (1) | BR112020015068A2 (fr) |
| CA (1) | CA3089068A1 (fr) |
| ES (1) | ES2948788T3 (fr) |
| IL (1) | IL276059B1 (fr) |
| MX (1) | MX2020007760A (fr) |
| RU (1) | RU2020125170A (fr) |
| SG (1) | SG11202007178VA (fr) |
| WO (1) | WO2019148087A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230301966A1 (en) * | 2021-07-30 | 2023-09-28 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-htp) exposure |
| AU2022320730A1 (en) * | 2021-07-30 | 2024-03-14 | Evecxia Therapeutics, Inc. | 5-hydroxytryptophan gastroretentive dosage forms |
| US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| DE102022103658A1 (de) * | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658038A (en) | 1982-10-07 | 1987-04-14 | Research Foundation For Mental Hygiene, Inc. | N-acylated 5-hydroxytryptophan amide derivatives |
| FR2654931B1 (fr) * | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| ES2248908T7 (es) | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
| US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (fr) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
| EP1746985A4 (fr) * | 2004-05-21 | 2010-08-11 | Univ Duke | Procede destine a augmenter les effets des inhibiteurs de la reabsorption de la serotonine |
| US20070213370A1 (en) * | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
| US8969400B2 (en) | 2007-10-01 | 2015-03-03 | Duke University | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound |
| CN102202656A (zh) | 2008-08-15 | 2011-09-28 | 蒂宝制药公司 | 治疗和预防cns障碍的胃滞留药用组合物 |
| RU2012133467A (ru) * | 2010-02-05 | 2014-02-10 | Фосфейдженикс Лимитед | Композиция носителя |
| EP2629615B1 (fr) * | 2010-10-22 | 2018-10-10 | Duke University | Formulations à libération prolongée de 5-hydroxytryptophane en tant que complément à des thérapies pro-sérotonergiques |
| CN103554005A (zh) | 2013-11-22 | 2014-02-05 | 长沙理工大学 | 一种左旋5-羟基色氨酸的简便合成新方法 |
-
2019
- 2019-01-28 WO PCT/US2019/015391 patent/WO2019148087A1/fr unknown
- 2019-01-28 AU AU2019211458A patent/AU2019211458A1/en active Pending
- 2019-01-28 IL IL276059A patent/IL276059B1/en unknown
- 2019-01-28 BR BR112020015068-1A patent/BR112020015068A2/pt unknown
- 2019-01-28 RU RU2020125170A patent/RU2020125170A/ru unknown
- 2019-01-28 KR KR1020207024221A patent/KR20200116110A/ko not_active Application Discontinuation
- 2019-01-28 ES ES19743636T patent/ES2948788T3/es active Active
- 2019-01-28 CN CN201980021717.5A patent/CN111902137A/zh active Pending
- 2019-01-28 SG SG11202007178VA patent/SG11202007178VA/en unknown
- 2019-01-28 JP JP2020541352A patent/JP2021511365A/ja active Pending
- 2019-01-28 EP EP19743636.3A patent/EP3746058B1/fr active Active
- 2019-01-28 US US15/733,423 patent/US11337963B2/en active Active
- 2019-01-28 CA CA3089068A patent/CA3089068A1/fr active Pending
- 2019-01-28 MX MX2020007760A patent/MX2020007760A/es unknown
-
2023
- 2023-07-21 JP JP2023119314A patent/JP2023153871A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11337963B2 (en) | 2022-05-24 |
| EP3746058B1 (fr) | 2023-06-07 |
| CN111902137A (zh) | 2020-11-06 |
| EP3746058C0 (fr) | 2023-06-07 |
| EP3746058A1 (fr) | 2020-12-09 |
| IL276059B1 (en) | 2024-04-01 |
| WO2019148087A1 (fr) | 2019-08-01 |
| IL276059A (en) | 2020-08-31 |
| JP2023153871A (ja) | 2023-10-18 |
| RU2020125170A (ru) | 2022-02-28 |
| JP2021511365A (ja) | 2021-05-06 |
| ES2948788T3 (es) | 2023-09-19 |
| AU2019211458A1 (en) | 2020-08-06 |
| US20210346345A1 (en) | 2021-11-11 |
| MX2020007760A (es) | 2020-10-28 |
| CA3089068A1 (fr) | 2019-08-01 |
| KR20200116110A (ko) | 2020-10-08 |
| BR112020015068A2 (pt) | 2021-01-05 |
| EP3746058A4 (fr) | 2021-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2582482B (en) | CASZ compositions and methods of use | |
| IL268895A (en) | Compositions and methods for inhibiting proteins with specific binding | |
| IL272514A (en) | Preparations and methods for genome modification | |
| HK1252757A1 (zh) | 用於降解錯誤折疊的蛋白質的組合物和方法 | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| IL270714A (en) | Liver organoid preparations, methods for their preparation and their uses | |
| IL276059A (en) | Compositions and methods for improving 5-hydroxytryptophan bioavailability | |
| IL280709B2 (en) | Converted indoles and methods of using them | |
| IL268684A (en) | Preparations and methods for immuno-oncology | |
| IL275694A (en) | Unnatural nucleotide compounds and methods of using them | |
| IL269590A (en) | Methods and compositions for reducing immunogenicity | |
| GB202201861D0 (en) | Novel methods and compositions | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL276135A (en) | Preparations and methods of use | |
| IL274524B2 (en) | Preparations and methods for aquaculture | |
| IL266840A (en) | History of tyrosine and preparations containing them | |
| PL3867446T3 (pl) | Kompozycje kleju do cylindra typu yankee i sposoby użycia tych kompozycji | |
| GB2568562B (en) | Moldable compositions and methods of using thereof | |
| EP3509614A4 (fr) | Méthodes et compositions pour le traitement de la maladie de lafora | |
| IL283703A (en) | A polymorphic form of meisoindigo and a different formulation of meisoindigo | |
| EP3313399A4 (fr) | Compositions et procédés d'inhibition de rit1 | |
| SG11202002351SA (en) | Poloxamer compositions and methods of making and using same | |
| PL3445730T3 (pl) | Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania | |
| ZA202201719B (en) | Stable polymorphic form of 6-fluoro-9-methyl-9h-beta-carboline and uses thereof |